



Platelets and infection – an emerging role of platelets in viral infection

Alice Assinger^{1,2*}

¹ Department of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria

² Department of Medicine, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden

Edited by:

Olivier Garraud, Institut National de la Transfusion Sanguine, France

Reviewed by:

Bo Shen, University of Illinois at Chicago, USA

Mirta Schattner, Institute of Experimental Medicine, Argentina

*Correspondence:

Alice Assinger, Department of Physiology and Pharmacology, Medical University of Vienna, Schwarzschanerstrasse 17, Vienna A-1090, Austria
e-mail: alice.assinger@meduniwien.ac.at

Platelets are anucleate blood cells that play a crucial role in the maintenance of hemostasis. While platelet activation and elevated platelet counts (thrombocytosis) are associated with increased risk of thrombotic complications, low platelet counts (thrombocytopenia) and several platelet function disorders increase the risk of bleeding. Over the last years, more and more evidence has emerged that platelets and their activation state can also modulate innate and adaptive immune responses and low platelet counts have been identified as a surrogate marker for poor prognosis in septic patients. Viral infections often coincide with platelet activation. Host inflammatory responses result in the release of platelet activating mediators and a pro-oxidative and pro-coagulant environment, which favors platelet activation. However, viruses can also directly interact with platelets and megakaryocytes and modulate their function. Furthermore, platelets can be activated by viral antigen-antibody complexes and in response to some viruses B-lymphocytes also generate anti-platelet antibodies. All these processes contributing to platelet activation result in increased platelet consumption and removal and often lead to thrombocytopenia, which is frequently observed during viral infection. However, virus-induced platelet activation does not only modulate platelet count but also shape immune responses. Platelets and their released products have been reported to directly and indirectly suppress infection and to support virus persistence in response to certain viruses, making platelets a double-edged sword during viral infections. This review aims to summarize the current knowledge on platelet interaction with different types of viruses, the viral impact on platelet activation, and platelet-mediated modulations of innate and adaptive immune responses.

Keywords: platelets, viruses, thrombocytopenia, thrombosis, immune response

INTRODUCTION

From an evolutionary perspective, the cellular mediators of hemostasis and immune defense have not always been separated. In invertebrates, a cell type called hemocyte protects the host from invading microbes and the same cell also prevents “blood” (i.e., hemolymph) loss upon injury by triggering coagulation (1, 2). In highly developed species, hemostasis and immune response have been divided and leukocytes resume the immune response functions, while platelets maintain hemostasis (2).

For decades, these two systems were thought to act independently, but this concept has recently been challenged. Emerging evidence suggests that the boundaries between coagulation and immune defense are actually not as clear-cut as originally supposed. A new concept of involvement of immune cells in hemostasis, termed immunothrombosis, has been recently proposed, which assumes a function of innate immune cells in thrombosis (3). On the other hand, an important role of platelets in immune response becomes more and more apparent (4–7).

In 1882, Bizzozzer discovered platelets as the third morphological element in blood and elucidated the function of these cells in hemostasis and thrombosis (8). For a long time, platelets and their granule content were thought to mainly mediate the activation of the coagulation system and the recruitment of further platelets

to stop blood loss upon injury. Unwanted platelet activation was noted to occur as a response to internal injuries, for example, denudation and erosion of the endothelial surface or rupture of an atherosclerotic plaque (9). Consequently, platelets were assumed to be responsible for the lethal steps of cardiovascular diseases, where unstable thrombi occlude small vessels, thereby compromising oxygen supply of target organs. Nevertheless, platelets are involved in far more processes and they respond to and interact with far more triggers than initially thought. Besides their central role in hemostasis, platelets assist and modulate inflammatory reactions and immune responses by direct interaction with leukocytes as well as endothelial cells and via release of soluble inflammatory mediators that enhance recruitment of leukocytes and trigger their activation (2, 4, 6, 10). Platelets also express surface receptors, such as lectins, integrins, and toll-like receptors (TLR), allowing them to directly interact with several pathogens. Moreover, they express Fc receptors by which they can recognize immunocomplexes.


Thus, platelet activation does not only occur in response to injury and is not only limited to hemostatic processes but also modulates host response and virus survival (3–5, 7, 10–12). Therefore, potential immune-modulatory side effects should be considered during anti-platelet therapy.

To date, the role of platelets in response to invading pathogens is not fully understood. Platelet–microbe interactions seem to be beneficial for the host due to up-regulation of immune responses. However, platelet interaction with invading pathogens is also speculated to benefit virus or bacteria, as platelets provide shelter against leukocytes, antiviral agents, and antibiotics. Moreover, the stickiness of platelets might attenuate microbe–endothelial interactions and facilitate infection by similar mechanisms to those recently described for platelet interactions with circulating tumor cells (13).

This review aims to summarize the current knowledge on platelet interaction with different types of viruses, the viral impact on platelet activation, and platelet-mediated modulations of innate and adaptive immune responses.

MECHANISMS OF VIRUS-INDUCED THROMBOCYTOPENIA

Platelets are, after erythrocytes, the second most abundant cell population in the blood. Normal platelet counts range from 150,000 to 450,000 platelets per microliter. Thrombocytopenia, which represents a drop in platelet count caused by either decreased platelet production or increased platelet destruction, is associated with an increased bleeding risk. Thrombocytopenia is frequent following viral infections and viruses use a variety of distinct strategies to decrease the levels of circulating platelets. The different mechanisms of how virus infection can interfere with platelet production and might trigger platelet destruction are summarized in the first chapter and **Figure 1**. As virus-mediated thrombocytopenia is often multifactorial and differs between virus infections, the mechanisms by which viruses trigger



thrombocytopenia are separately discussed for the most prominent viruses and an overview on the receptors involved in direct platelet–virus interactions is depicted in **Figure 2**.

DECREASED PLATELET PRODUCTION

Platelets are produced in the bone marrow by megakaryocytes, which develop from hematopoietic stem cells. Megakaryocytes first undergo lineage commitment, followed by endomitosis resulting in polyploidy (14). Polyploidy is a state where one cell comprises multiple sets of chromosomes and this represents an important step in megakaryopoiesis. After endoplasmatic maturation, megakaryocytes form proplatelets, which bud off thousands of platelets and microparticles into the blood stream (15). Megakaryopoiesis is triggered by a variety of cytokines (e.g., GM-CSF, IL-3, IL-6, IL-11, FGF4, and SDF-1), with **thrombopoietin (TPO)** being the most important. Nevertheless, TPO does not only trigger megakaryocyte development but also fulfils an important role in maintaining stem cells (16).

Viruses can modulate platelet production at various steps of development. They are able to influence the cytokine profile of the host, resulting in altered TPO production in the liver. Examples of this include: simian immunodeficiency virus (SIV), which triggers TPO production via up-regulation of tumor growth factor (TGF) β (17); **human herpes virus 6**, which can interfere with TPO-inducible megakaryocytic colony formation (18); human

herpes virus 7, which impairs the survival and differentiation of megakaryocytes (19).

Some viruses also directly interfere with TPO production by destruction of liver tissue as shown for **hepatitis C virus (HCV)** (20). The resulting drop in TPO production results in delayed megakaryocyte development and a decrease in platelet production. Other viruses infect bone marrow stromal cells and hematopoietic stem cells, resulting in altered cytokine production and decreased number of progenitor cells, thereby disturbing hematopoiesis (21).

Human immunodeficiency virus (HIV), **cytomegalovirus (CMV)**, and **HCV** are known to replicate in megakaryocytes (22–24) and many more viruses can interact with megakaryocytes modulating their proliferation and function (23, 25–29). Viral infection of megakaryocytes can increase apoptosis and decreases the maturation and ploidy of megakaryocytes. Moreover, virus-infected megakaryocytes have been shown to express less surface c-Mpl, which is the receptor for TPO (30). An overview on the different mechanisms on how viruses can interfere with platelet production is depicted in **Figure 1**.

ENHANCED PLATELET DESTRUCTION

While thrombocytopenia induced by decreased platelet production is observed at later stages of infection, rapidly induced thrombocytopenia in response to viral infections is mediated via enhanced platelet destruction.

The most rapid way of platelet destruction occurs via direct interaction between platelets and viruses. Platelet–virus interaction can occur via a variety of receptors and are mainly mediated by integrins, surface lectins, and TLR (25, 31, 32) (see **Figure 2**). Platelets can bind CMV via TLR2, which triggers platelet activation and degranulation and results in enhanced platelet interaction with neutrophils (32). Encephalomyocarditis virus (EMCV) was recently shown to interact with platelet TLR7, which also leads to platelet degranulation and direct platelet–neutrophil interactions (33). Platelet fragments subsequently get phagocytized by neutrophils, thereby contributing to the drop in platelet count (33).

Rotavirus utilizes the collagen receptor GPIa/IIa to bind to platelets (25, 34), while **hantavirus** and **adenoviruses** interact with platelets via the fibrinogen receptor GPIIb/IIIa (35). However, GPIIb/IIIa does not seem to be the unique receptor for platelet–adenovirus interaction, as inhibition of GPIIb/IIIa does not alter platelet internalization of adenoviruses (36). In addition, hantavirus-infected endothelial cells can bind to quiescent platelets via GPIIb/IIIa (37), which results in platelet activation and clearance but might also influence vascular permeability (38).

GPIIb/IIIa is the most abundant platelet integrin and displays bi-directional signaling functions. Inside-out signaling, which is positively regulated by various platelet agonists, is mediated by intracellular protein–protein interactions and biochemical reactions that regulate GPIIb/IIIa affinity (39). These intracellular processes triggering GPIIb/IIIa activation are complex and include recruitment of talin, which separates the GPIIb and the GPIIIa subunits, and kindlins, which are involved in GPIIb/IIIa activation (40) independent of talin recruitment (41). Further, G protein subunit $G\alpha_{13}$ directly binds to the cytoplasmic domain of GPIIIa and promotes ligand binding to GPIIb/IIIa (42).




FIGURE 2 | Platelet receptors for viruses: platelets and viruses can directly interact via a plethora of surface receptors. CMV binds to platelets via TLR2, EMCV interacts via TLR7, rotavirus utilizes GPIa/IIa to bind to platelets and hantavirus and adenovirus interact with platelets via GPIIb/IIIa. EBV–platelet interaction occurs via CR2. HIV and DV bind to lectin receptors such as CLEC-2 and DC-SIGN. HIV further interacts with CXCR4 and CCL3 and CCL5. Platelets express the Cocksackie virus-specific receptor, CAR, and HCV interacts with platelets via GPVI. CAR, Cocksackie-adenovirus receptor; CLEC-2, C-type lectin domain family 2; CCL, chemokine (C–C motif) ligand; CMV, cytomegalovirus; CR, complement receptor; CXCR4, C–X–C chemokine receptor type 4; EBV, Epstein–Barr virus; EMCV, encephalomyocarditis virus; DC-SIGN, dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin; DV, Dengue virus; FcγRII, Fc receptor γ II; GP, glycoprotein; HCV, hepatitis virus C; HIV, human immunodeficient virus; IgG, immunoglobulin G; TLR, toll-like receptor;

Outside-in signaling via receptor binding promotes actin polymerization and platelet spreading (39) and can thereby enhance virus attachment to endothelial cells but also promote platelet clearance.

Epstein–Barr virus (EBV) interaction with platelets occurs via complement receptor 2 (CR2) (43). HIV and dengue virus activate platelets by binding to lectin receptors such as C-type lectin domain family 2 (CLEC-2) and cell-specific intercellular adhesion molecule-3-grappling non-integrin (DC-SIGN) (44). Platelets and/or megakaryocytes can further interact with HIV envelope proteins via C–X–C chemokine receptor type 4 (CXCR4) or via chemokine (C–C motif) ligand (CCL) 3 (MIP-1 α) and 5 (RANTES) (25). However, HIV-1 changes its co-receptor usage from CCR5 to CXCR4 only after many years of infection and this receptor change represents a switch to non-CD4-dependent platelet activation at late stages of disease.

In addition, platelets express the Coxsackie virus-specific Coxsackie-adenovirus receptor (CAR) (45) and HCV interacts with platelets via collagen receptor GPVI (46).

These direct interactions often result in platelet activation and adhesion of activated platelets to leukocytes. Platelet binding to neutrophils triggers phagocytosis of platelets (33, 47) and platelet activation itself promotes platelet clearance in spleen and liver (48).

However, platelets are not only activated by direct interactions with viruses. Host defense mechanisms in response to viral infections can also lead to platelet activation. For example, many viral infections lead to systemic inflammation, which in turn triggers platelet activation and decreases platelet life span (49). Among others, influenza virus, rhinovirus, and CMV infection result in up-regulation of cytokines, such as interleukin 6 (IL-6), in target cells (50).

Platelets can be activated by these cytokines, leading to platelet–leukocyte interactions, which foster leukocyte and endothelial activation, further amplifying platelet activation and enhancing their clearance by splenic macrophages or Kupffer cells in the liver (45). Monocytes that encounter dengue virus, for example, start generating platelet activating factor (PAF) (51), which is a lipid mediator that triggers platelet activation. This leads to enhanced apoptosis of platelets and accelerates platelet clearance in secondary dengue infection (52).

Several virus infections activate the coagulation cascade via induction of tissue factor (TF) expression in target cells. Generation of thrombin by the activated coagulation cascade causes platelet activation and subsequent clearance via protease activating receptor (PAR) signaling (53). PARs on platelets, endothelial cells, and leukocytes are important modulators during viral infections, which modulate innate immune responses and exert positive and negative effects on TLR-dependent responses (53).

Platelets also recognize viral particles coated with immunoglobulins via their Fc γ RII receptor, which results in Fc receptor-mediated platelet activation, aggregation, and platelet clearance (54, 55). Fc γ RII-mediated platelet activation depends on IgG and GPIIb/IIIa engagement and involves ADP and thromboxane A₂ (TxA₂) feedback mechanisms to cause platelet aggregation, which is further enhanced by CXCL4 (56).

Furthermore, B-lymphocyte production of antibodies against some viruses has been shown to interfere with platelet survival. These antibodies, which usually target surface glycoproteins of viruses, show a cross-reactivity with platelet surface integrins such as GPIIb/IIIa or GPIb-IX-V (38). This so called idiopathic thrombocytopenic purpura (ITP) or platelet autoantibody-induced thrombocytopenia has been described for HCV, HIV, CMV, EBV, hantavirus, varicella zoster virus, herpes viruses, and severe acute respiratory syndrome coronavirus (38).

Additionally, platelet destruction in response to viral infections can occur due to disturbed portal vein pressure and enhanced sequestration of platelets by the enlarged spleen as is the case in HCV infection (57).

MULTIFACTORIAL MECHANISMS LEADING TO THROMBOCYTOPENIA

Thrombocytopenia in response to viral infections is often multifactorial. In viral hepatitis, thrombocytopenia is caused by platelet-specific glycoprotein antibodies (58) as well as by immune complexes bound to the platelet surface (59). In the case of HCV, thrombocytopenia can be reversed using a selective thrombin receptor agonist (60), indicating that coagulation, inflammation, and platelet activation play a role in HCV-induced decrease of platelet count. HCV also indirectly affects megakaryopoiesis (25, 59). HCV-induced liver dysfunction results in a decrease in TPO production, which in turn results in impaired platelet production in the bone marrow (20). The recovery of TPO levels and increase in platelet count following successful liver transplantations in HCV-infected individuals (20) emphasizes the importance of this mechanism in HCV-induced thrombocytopenia. Moreover, portal hypertension leads to platelet activation and shortens platelet survival due to increased splenic platelet sequestration (57). However, treatment aiming at reversing portal hypertension did not always correct thrombocytopenia (20).

Human immunodeficiency virus-induced thrombocytopenia is caused by multiple mechanisms. The effects of HIV on megakaryocyte development were recently reviewed in Ref. (30). In brief, HIV results in impaired survival of bone marrow megakaryocytes and their precursors. HIV also decreases the number and activity of human progenitor cells and decreases megakaryocyte maturation and ploidy. HIV surface glycoprotein gp120 leads to increased megakaryocyte apoptosis *in vitro* due to increased TGF β and down-regulation of the proliferation-inducing ligand tumor necrosis factor ligand superfamily member 13 (TNFSF13). Further, gp120 interacts with CD4, which is expressed by immature megakaryocytes, which also express CCR5, and leads to their infection (61). Furthermore, HIV infection of megakaryocytes can lead to reduced TPO receptor (c-Mpl) expression.

In dengue virus infection, platelet production is impaired by suppression of megakaryopoiesis via infection of hematopoietic progenitor cells or indirectly via altered cytokine levels in the bone marrow due to impaired stromal cell function (51). Platelets from patients with dengue infection present signs of activation, mitochondrial dysfunction, and enhanced apoptosis, which may contribute to the genesis of thrombocytopenia

(62, 63). Further, enhanced destruction of platelets occurs due to cross-reaction of platelets with anti-dengue virus antibodies. Dengue virus-induced anti-non-structural protein-1 (NS-1) induces complement-mediated lysis of platelets and thereby further accelerates thrombocytopenia (64). NS-1 can also activate endothelial cells and leads to increased vascular permeability and further platelet activation (65). Dengue virus-infected patients show increased levels of E-selectin on their endothelial cell surface, which promotes adhesion and clearance of platelets (65, 66) as well as enhanced activation of the coagulation cascade (67).

Arenaviruses infection by either lymphocytic choriomeningitis virus (LCMV) or Junin virus results in thrombocytopenia and decreased agonist-induced platelet responses in mice (68, 69). As a consequence, platelet depletion in LCMV-infected mice results in lethal hemorrhagic anemia (68). This effect is caused by diminished platelet responses, rather than solely a drop in platelet count. The underlying mechanism of altered platelet production and reduced platelet reactivity was found to rely on virus-induced production of interferon (IFN) α/β (68, 69). Junin virus mainly infects CD34⁺ cells not megakaryocytes but impairs proplatelet formation and platelet release via IFN α/β receptor signaling (69). IFN α/β receptor signaling represents an important paracrine repressor of megakaryopoiesis, which directly inhibits TPO-induced signaling through induction of suppressor of cytokine signaling 1 (SOCS-1) (70), induction of 2'5'-oligoadenylate synthetase (OAS) (68), and decrease of nuclear factor erythroid 2 (NF-E2) expression (69).

Hantavirus can directly interact with and activate platelets via GPIIb/IIIa (35) and infection of megakaryocytes with hantavirus induces the up-regulation of human leukocyte antigen (HLA) class I molecules on the megakaryocyte surface, which leads to cytotoxic T-lymphocyte-mediated destruction of megakaryocytes (27).

Viruses also possess enzymes, which can modulate platelet functions. For example, **Influenza virus exhibits neuraminidase (sialidase), which hydrolyses the terminal sialic acid residues from host cell receptors and thereby decreases the life span of platelets by targeting platelets for rapid clearance in the liver and spleen** (71). As another example, mycoviral neuraminidase has been shown to reduce platelet life span by cleaving sialic acid in the platelet membrane (72). Besides the effect on platelet life span, neuroaminidase further alters megakaryocyte ploidy as well as morphology and size of platelets (73). Newcastle virus can directly disrupt platelet cell membrane, resulting in platelet lysis (74). Human parvovirus 19 cannot reproduce in megakaryocytes, but triggers a drop in platelet count via platelet activation (75).

Despite its effects on TPO generation, direct interaction of the non-human SIV with platelets results in platelet-monocyte aggregate formation, which promotes monocyte differentiation into a more inflammatory phenotype. Furthermore, platelet activation triggers clearance of platelets (76, 77) as platelets become recognized by macrophages in the spleen, leading to a rapid drop in platelet count.

It is currently unclear if, and to what extent, viruses or the host could benefit from thrombocytopenia. It has been suggested that down-regulation of hematopoiesis, for example, in dengue virus infection might have a protective role for the microenvironment to limit injury during elimination of infected cells (78).

ANTIVIRAL EFFECTS OF PLATELETS

Direct interaction between platelets and viruses has been observed in various viral infections and could be proven by *in vitro* studies. The interactions leading to platelet activation do not only result in enhanced platelet clearance, the elimination of virus-laden platelets also contributes to the clearance of virus particles (25).

An overview on the different mechanisms by which platelets can interfere with virus infection is given in **Figure 3**. Platelet activation in response to direct and indirect interaction with viruses results in platelet activation and degranulation. Platelet α -granules provide platelet-mediated host defense mechanisms, as they contain kinocidins and microbicidal proteins important for antiviral host defense. Kinocidins have immune-modulatory functions including chemotaxis and activation of various immune cells (79). They can differentiate between host and pathogen cell membranes and distinct microbial spectra under different pH conditions. Thrombin, which is produced upon inflammation and injury, can proteolytically cleave kinocidins and platelet antimicrobial peptides resulting in cleavage products with a stronger and broader range of antimicrobial activity (49, 80). Pathogens can also cleave kinocidins on distinct sites, which potentially results in their inactivation.

The most abundant platelet kinocidin is platelet factor 4 (PF-4/CXCL4). **CXCL4** is released into the blood stream upon tissue injury, inflammation, oxidative stress, or pathogen stimulation such as platelet-virus interactions. CXCL4 has been identified as a **broad-spectrum HIV-1 inhibitor** and suppresses HIV-1 infection of T-lymphocytes via steric inhibition by binding of CXCL4 proximal to the CD4 binding site on gp120 (81, 82).

Other important chemokine released during viral infections in host defense are CCL5 and CCL3 (83). **CCL5 and CCL3 have been identified as major HIV-suppressive factors** produced by cytotoxic T-lymphocytes (84) and also platelet-derived CCL5 and CCL3 could play a role in this process. It is currently unclear whether the effect of CCL5 on inhibiting HIV infection is due to perturbation of the viral envelope and/or due to competitive binding to its receptors (primarily CCR5) (79). HIV gp41 is able to decrease CCL5 release from platelets, thereby directly counteracting the antiviral responses of platelets (85). While CXCL4 is mainly platelet-derived, CCL5 can be released by various cells types and indeed, a variety of viruses has been shown to induce CCL5 release [reviewed in Ref. (86)].

CCL5 is further involved in viral lung diseases (87). It represents an important chemokine during the development and resolution of a **pulmonary leukocyte response to influenza A virus** infection in mice (88). CCL5 interaction with its receptor CCR5 provides an **anti-apoptotic signal for macrophages during influenza virus** infection (89) and is important for cell survival during viral infections. CCL5 has multifaceted roles in HCV infection, as it modulates inflammatory reactions and tissue injury and also induces the **up-regulation of T-lymphocyte helper cells type 1 (Th1)** (90).

Upon activation, platelets release β -defensins, which have been shown to **neutralize a variety of viruses** (91). Platelet antimicrobial peptides **PD3** (KNGRKLLDLQAALY) and **PD4** (AALYKKKI-IKKLLES), which are platelet α -granule-derived molecules, have also been demonstrated to **potently reduce viral titers** of vaccinia virus (92). Other platelet-derived antimicrobial peptides, for




FIGURE 3 | Effects of activated platelets on virus infection: upon activation, platelets release their α -granules, containing high amounts of CXCL4, which up-regulates coagulation and leukocyte recruitment.

Moreover, CXCL4 decreases HIV infection but also enhances liver fibrosis. CCL5, another α -granule-derived chemokine, also decreases HIV infection and enhances T_{H1} lymphocyte responses in HCV infection and serves as a survival signal for macrophages in influenza infection. Platelets release PMPs and β -defensins from their α -granules, which mediate virus neutralization. They protect splenocytes from necrosis in LCMV infection. Platelet dense granules contain 5-HT, which enables liver regeneration but also HBV and HCV infection. Platelet activation leads to the expression and release of CD154 and CD62P, which allow direct interaction between platelets and leukocytes. Platelet interaction with B-lymphocytes enhances germinal center formation

and antiviral IgG production. Platelets trigger T-lymphocyte differentiation and cytotoxicity as well as survival and differentiation of monocytes. In neutrophils, platelet adhesion stimulates ROS production and boosts phagocytosis. Platelet interaction with dendritic cells promotes their maturation and facilitates antigen presentation. Finally, platelet activation results in interaction and activation of further platelets, which triggers platelet aggregation and amplifies the above described processes. CCL5, chemokine (C-C motif) ligand 5; CXCL4, C-X-C chemokine ligand 4, GP, glycoprotein; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficient virus; IgG, immunoglobulin G; LCMV, lymphocytic choriomeningitis; PMPs, Platelet antimicrobial peptides; PSGL-1, P-selectin (CD62P) glycoprotein ligand-1; sCD154, soluble CD154/CD40 ligand; Th1, T-helper lymphocyte type 1; 5-HT, serotonin.

example, thymosin beta 4, CXCL7, or cleavage products of antimicrobial peptides (fibrinopeptide A and B, thrombicidins), do not directly act against viral infections but could prevent the host from bacterial super-infections (49).

The highest amounts of serotonin in blood are stored in platelet dense granules, which are also released upon platelet activation. Serotonin was found to be an important mediator of liver regeneration (93, 94) and also mediates early T-lymphocyte stimulation (95).

Platelet degranulation further results in surface expression of P-selectin, which is part of the inner α -granule membrane, which

fuses with the outer platelet membrane upon granule exocytosis. P-selectin interacts with its counter-receptor P-selectin glycoprotein ligand-1 (PSGL-1), which is constitutively expressed on the surface of leukocytes (96). Platelet interactions with leukocytes mediate immune responses during viral infections (79). Direct interaction with platelets leads to activation of leukocytes, resulting in enhanced phagocytosis and reactive oxygen production of neutrophils, as well as neutrophil extracellular trap formation. The platelet-monocyte interaction results in an increased activation and differentiation and boosts monocyte surface expression of TF and formation of microparticles (96).




FIGURE 4 | Adverse effects of platelets in viral infections: platelets can shelter viruses like HIV, HVC, HBV, and influenza and facilitate their transportation throughout the circulation, thereby enabling *de novo* infections at distal sites. Platelet–virus interaction often results in platelet activation and subsequent release of α -granules and dense granules. CXCL4 from α -granules has been demonstrated to enhance HIV infection of macrophages and enhance liver fibrosis in hepatitis. CCL5 enhances T-lymphocyte recruitment and thereby promotes HIV infection of T-lymphocytes. Dense granule-derived 5-HT was shown to

boost HBV and HCV infection by decreasing the entry of cytotoxic T-lymphocytes. Direct interaction of platelets with leukocytes facilitates infection of leukocytes and enhances both leukocyte activation and inflammation. Activation of platelets leads to activation and recruitment of further platelets and enhances pro-coagulatory processes. CCL5, chemokine (C–C motif) ligand 5; CXCL4, C–X–C chemokine ligand 4, GP glycoprotein; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficient virus; sCD154, soluble CD154/CD40 ligand; 5-HT, serotonin.

In response to CMV and EMCV, platelet–virus interaction results in stimulation of TLRs, which trigger platelet degranulation and rapid direct interaction of platelets and neutrophils (32, 33). Of note, platelets were shown to decrease EMCV counts in a TLR7-dependent fashion and contribute to host survival while no pro-thrombotic consequences of platelet TLR7 and EMCV interaction could be observed (33).

Platelets recruit dendritic cells to sites of injury or infection (97) and products released from platelets promote maturation of dendritic cells and enhance their antigen presenting capacity (98, 99).

Platelet–leukocyte interaction and modulation of leukocyte functions can be further accelerated by CD40 ligand (CD40L/CD154) binding to CD40. Platelets express and secrete (soluble) CD154, thereby triggering host responses and boosting inflammation.

Platelets directly interact with T-lymphocytes and B-lymphocytes and modulate their function via direct cell–cell interaction as well as soluble mediators (100). Platelet-released CXCL4 and CCL5 enhance pro- and anti-inflammatory cytokine production of T-lymphocytes (101). CXCL4 represents an important mediator in T-cell differentiation, which leads to an increase in regulatory T-lymphocytes (102) and limits Th17 differentiation (103).

Platelets additionally enhance T-lymphocyte-mediated germinal center formation (104) and they can independently up-regulate adenovirus specific IgGs via CD154 (105).

Binding of IgG-coated viruses causes platelet expression of CD154 and CCL5, which in turn primes protective T-cell-mediated immunity (79). Platelets in mice infected with lymphocytic choriomeningitis virus were found to be responsible for efficient cytotoxic T-cell responses, which depended on platelet GPIIb (CD61) and CD154 (68). T-lymphocyte interaction with platelets also results in the activation of platelets, which amplifies the release of CCL5 (106).

In hepatitis virus B (HBV) infected mice, platelets were shown to be responsible for the intra-hepatic accumulation of virus-specific cytotoxic T-lymphocytes (107) and to mediate cytotoxic T-cell influx into liver tissue via P-selectin, which enhances viral clearance but also tissue damage (108). It was further shown an LCMV infection model that a drop in platelet count leads to necrotic destruction of splenocytes (109). This affects innate and adaptive immunity and leads to uncontrolled LCMV replication (109), indicating that platelets are necessary to maintain splenocyte survival.

ADVERSE EFFECTS OF PLATELET ACTIVATION IN VIRAL INFECTIONS

To date, it remains unclear if platelet–virus interactions are beneficial for the host or for the virus. Potential adverse effects of platelets in viral infections are summarized in Figure 4. HIV, for example, is internalized by platelets, which results in sheltering of virus particles from the host immune systems and allows dissemination

throughout the entire body [reviewed in Ref. (25)]. Moreover, in response to HIV interaction, platelets become activated and release CCL5, which results in the recruitment of highly susceptible target cells like T-lymphocytes and monocytes. It was demonstrated for influenza virus that platelets serve as a carrier for the virus in the circulation (72). Also HCV has been shown to take advantage of platelets as a safe transport system to reach the liver, where platelet activation further enhances the interaction of platelets and liver cells. This interaction prolongs the time for potential infection of liver tissue by the virus (46).

Virus-mediated activation of platelets and subsequent platelet-derived cytokine release not only protects the host but may also have unwanted implications for the host. While several reports indicate that CXCL4 is a broad-spectrum suppressor of HIV infection, one report indicates that platelet CXCL4 can also facilitate human macrophage infection with HIV-1 and potentiates virus replication (110). Furthermore, CXCL4 has been shown to mediate liver fibrosis in experimental mouse models (111), indicating that this chemokine could play a role in platelet-mediated acceleration of hepatitis-induced liver fibrosis.

Platelet-derived serotonin results in a delayed entry of activated cytotoxic T-lymphocytes into the liver, which slows down virus control and supports virus persistence in the liver (112). This results in aggravation of virus-induced immunopathology.

Megakaryocyte infection and subsequent modulation of platelet function by CMV have been speculated to be a reason for graft failure in allergenic bone marrow transplantation (25).

BLEEDING AND THROMBOTIC COMPLICATIONS IN RESPONSE TO VIRAL INFECTION

Primary and secondary hemostasis work tightly together. Imbalances of either system result in impaired function of the other. Activation of the coagulation cascade has been observed in various virus infections, including HIV, dengue, and Ebola virus infection, and might provide a host defense mechanism to limit pathogen dissemination (53). Changes in the activation of the coagulation cascade and modulation of platelet count and function, which are also observed during viral infections, lead to an increased risk of disseminated vascular coagulation (DIC), deep vein thrombosis (DVT) thrombosis, and hemorrhage in infected patients (38). Thrombocytopenia is a common result of viral infections and associated with an increased bleeding risk. Approximately 10% of HIV positive patients and up to 60% of patients with acquired immunodeficiency syndrome (AIDS) suffer from thrombocytopenia, which can lead to severe bleedings in these patients (30). In many viral infections, platelet function and aggregation in response to different agonists are diminished (25), causing bleeding complications in viral hemorrhagic fevers (VHF) (51). VHF outbreaks lead to the deaths of thousands of people every year and are caused by different enveloped RNA viruses, which include *Arenaviridae* (e.g., Lassa virus), *Bunyaviridae* (e.g., hantavirus), *Filoviridae* (e.g., Marburg and Ebola virus), and *Flaviviridae* (e.g., dengue virus).

Of note, it was recently shown that a reduction in platelet count of more than 85% is necessary for hemorrhages to occur, indicating that a very low percentage of platelets are sufficient to maintain vascular integrity (109). In an LCMV model, it was

demonstrated that even severe thrombocytopenic mice develop only local hemorrhages at sites of inflammation and that LCMV-dependent bleedings are a result of IFN α/β signaling-induced platelet dysfunction (68). Mice lacking functional IFN α/β receptor show less severe anemia and hemorrhages due to restored platelet aggregation capacity during LCMV infection (68). This indicates that platelet dysfunction has more tremendous effects than thrombocytopenia in these pathologies. Of note, many VHF viruses inhibit platelet function. Junin virus, causative of Argentinean hemorrhagic fever, induces IFN α/β signaling-dependent decrease in platelet production and function (69). Ebola virus also induces an increase in IFN α , which correlated with increased fatality (113). Ebola infection further triggers TF expression, which is associated with Ebola hemorrhagic fever (114). Hantavirus and Lassavirus also abrogate platelet responses via plasma-mediated platelet inhibition and/or direct interaction (37, 115).

Although thrombocytopenia is frequently observed in patients with dengue infections, bleedings are rare. However, if bleedings do occur they are associated with high mortality risk. Of note, in dengue virus-infected patients, platelet count does not predict bleeding risk. However, systemic platelet activation might contribute to the pro-coagulatory state in these patients, which frequently develop DIC (67). Moreover, elevated platelet activation is associated with plasma leakage (116). H1N1 influenza infection enhances activation of circulating platelets (117) and results in increased events of thrombosis (118).

In line with the observation that platelet dysfunction increases the risk of hemorrhages and therefore mortality, it has been demonstrated that pharmacological inhibition of either platelets or the coagulation cascade increases the mortality of H1N1-infected mice (53). Thus, aspirin treatment, which inhibits platelet activation via inhibition of cyclooxygenase and subsequent TxA₂ production, has been hypothesized to have worsened the incidence and severity of the influenza pandemics in the 1910s (119).

Taken together, viruses can either enhance platelet activation resulting in pro-thrombotic events or diminish platelet responses thereby leading to bleeding complications. Platelet count alone does not seem to be sufficient to predict adverse platelet effects and parameters like platelet activation and reactivity might be more accurate to predict thrombotic or bleeding risks in patients.

PLATELET-VIRUS INTERPLAY IN CARDIOVASCULAR DISEASE

Platelets are responsible for the lethal consequences of cardiovascular disease but emerging evidence suggests that they also play a role in the initiation and progression of atherosclerosis. Several viruses have been associated with cardiovascular disease and herpes simplex virus (HSV), HIV, CMV, HCV, EBV as well as influenza DNA, and/or protein has been found in atherosclerotic plaques (120, 121). Large cohort studies indicate that seropositivity for CMV or HCV represent an independent risk marker for cardiovascular diseases (122, 123), while other studies could not confirm this observation (121). CMV and HCV are further associated with increased graft rejection rates, restenosis following coronary angioplasty and transplant vascular sclerosis, indicating that latent virus re-activates during immunosuppression and contributes to adverse effects (121).

In animal studies, CMV increased T-lymphocyte influx into plaques (124) and neutrophil extravasation, which is further supported in the presence of platelets (32). Influenza virus infection correlates with acute coronary syndromes and myocardial infarction (125), while influenza seropositivity and cardiovascular disease show no clear correlation (121). Animal experiments revealed that influenza triggers inflammatory and thrombotic responses in atherosclerotic plaques (126) and reverses the protective role of high-density lipoproteins (127). Both mechanisms are likely to modulate platelet function and reactivity.

There is some discrepancy regarding the strength of data regarding HSV infection and cardiovascular disease and despite its pro-inflammatory responses, a negative association between EBV infection and cardiovascular disease has been observed.

Moreover, the association between HIV infection and cardiovascular disease remains controversial and anti-retroviral therapy itself alters platelet function (128) and represents an independent risk factor for atherosclerosis (121). Further studies are warranted to evaluate the contribution of platelet–virus interactions in cardiovascular disease.

CONCLUSION

Platelets and their released products have been reported to directly and indirectly suppress infection but also to support virus persistence in response to certain viruses, making platelets a double-edged sword during viral infections. Platelets are involved in a variety of complications in response to viral infection but also fulfill a pivotal role in retaining adequate host responses. Thrombocytopenia is a common complication in several viral infections and viruses exert various strategies to mediate platelet decay. The question, if thrombocytopenia is a viral strategy to evade immune responses or if it also has host protecting functions, seems to depend on the virus variant and the underlying pathology. Further studies are warranted to fully understand the role of platelets in viral infections and to gain a clear understanding of the effects of anti-platelet therapies in viral infections. These studies will help us to predict the benefit or drawback of platelets and their inhibition during viral infections.

ACKNOWLEDGMENTS

The author would like to thank Dr. Mattias Forsell and Dr. Rona Strawbridge for critical comments on the manuscript and the Austrian Science Fund for financial support (FWF-P24978).

REFERENCES

- Grigorian M, Hartenstein V. Hematopoiesis and hematopoietic organs in arthropods. *Dev Genes Evol* (2013) **223**:103–15. doi:10.1007/s00427-012-0428-2
- Weyrich AS, Lindemann S, Zimmerman GA. The evolving role of platelets in inflammation. *J Thromb Haemost* (2003) **1**:1897–905. doi:10.1046/j.1538-7836.2003.00304.x
- Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. *Nat Rev Immunol* (2013) **13**:34–45. doi:10.1038/nri3345
- von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. *Circ Res* (2007) **100**:27–40. doi:10.1161/01.RES.0000252802.25497.b7
- Morrell CN, Aggrey AA, Chapman LM, Modjeski KL. Emerging roles for platelets as immune and inflammatory cells. *Blood* (2014) **123**:2759–67. doi:10.1182/blood-2013-11-462432
- Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. *Nat Rev Immunol* (2011) **11**:264–74. doi:10.1038/nri2956
- Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. *Trends Immunol* (2004) **25**:489–95. doi:10.1016/j.it.2004.07.003
- Ribatti D, Crivellato E, Giulio Bizzozero and the discovery of platelets. *Leuk Res* (2007) **31**:1339–41. doi:10.1016/j.leukres.2007.02.008
- Badimon L, Chesebro JH, Badimon JJ. Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi. *Circulation* (1992) **86**:III74–85.
- Karshovska E, Weber C, von Hundelshausen P. Platelet chemokines in health and disease. *Thromb Haemost* (2013) **110**:894–902. doi:10.1160/TH13-04-0341
- Rondina MT, Weyrich AS, Zimmerman GA. Platelets as cellular effectors of inflammation in vascular diseases. *Circ Res* (2013) **112**:1506–19. doi:10.1161/CIRCRESAHA.113.300512
- Langer HF, Weber C, Gawaz M. The platelet – thrombosis and beyond. *Thromb Haemost* (2013) **110**:857–8. doi:10.1160/TH13-09-0805
- Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. *Nat Rev Cancer* (2011) **11**:123–34. doi:10.1038/nrc3004
- Patel SR, Hartwig JH, Italiano JE Jr. The biogenesis of platelets from megakaryocyte proplatelets. *J Clin Invest* (2005) **115**:3348–54. doi:10.1172/JCI26891
- Kuter DJ. Milestones in understanding platelet production: a historical overview. *Br J Haematol* (2014) **165**:248–58. doi:10.1111/bjh.12781
- de Graaf CA, Metcalf D. Thrombopoietin and hematopoietic stem cells. *Cell Cycle* (2011) **10**:1582–9. doi:10.4161/cc.10.10.15619
- Metcalf Pate KA, Lyons CE, Dorsey JL, Queen SE, Adams RJ, Morrell CN, et al. TGFbeta-mediated downregulation of thrombopoietin is associated with platelet decline in asymptomatic SIV infection. *J Acquir Immune Defic Syndr* (2014) **65**:510–6. doi:10.1097/QAI.0000000000000048
- Isomura H, Yoshida M, Namba H, Fujiwara N, Ohuchi R, Uno F, et al. Suppressive effects of human herpesvirus-6 on thrombopoietin-inducible megakaryocytic colony formation in vitro. *J Gen Virol* (2000) **81**:663–73. doi:10.1002/(SICI)1096-9071(199708)52:4<406::AID-JMV11>3.0.CO;2-E
- Gonelli A, Mirandola P, Grill V, Secchiero P, Zauli G. Human herpesvirus 7 infection impairs the survival/differentiation of megakaryocytic cells. *Haematologica* (2002) **87**:1223–5.
- Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F, et al. Thrombocytopenia associated with chronic liver disease. *J Hepatol* (2008) **48**:1000–7. doi:10.1016/j.jhep.2008.03.009
- Kolb-Maurer A, Goebel W. Susceptibility of hematopoietic stem cells to pathogens: role in virus/bacteria tropism and pathogenesis. *FEMS Microbiol Lett* (2003) **226**:203–7. doi:10.1016/S0378-1097(03)00643-8
- Chelucci C, Federico M, Guerriero R, Mattia G, Casella I, Pelosi E, et al. Productive human immunodeficiency virus-1 infection of purified megakaryocytic progenitors/precursors and maturing megakaryocytes. *Blood* (1998) **91**:1225–34.
- Li X, Jeffers LJ, Garon C, Fischer ER, Scheffel J, Moore B, et al. Persistence of hepatitis C virus in a human megakaryoblastic leukaemia cell line. *J Viral Hepat* (1999) **6**:107–14. doi:10.1046/j.1365-2893.1999.00140.x
- Crapnell K, Zanjani ED, Chaudhuri A, Ascensao JL, St Jeor S, Maciejewski JP. In vitro infection of megakaryocytes and their precursors by human cytomegalovirus. *Blood* (2000) **95**:487–93.
- Flaujac C, Boukour S, Cramer-Borde E. Platelets and viruses: an ambivalent relationship. *Cell Mol Life Sci* (2010) **67**:545–56. doi:10.1007/s00018-009-0209-x
- Yang M, Ng MH, Li CK. Thrombocytopenia in patients with severe acute respiratory syndrome (review). *Hematology* (2005) **10**:101–5. doi:10.1080/10245330400026170
- Lutheke N, Raftery MJ, Lalwani P, Lee MH, Giese T, Voigt S, et al. Switch to high-level virus replication and HLA class I upregulation in differentiating megakaryocytic cells after infection with pathogenic hantavirus. *Virology* (2010) **405**:70–80. doi:10.1016/j.virol.2010.05.028
- Passos AM, Treitinger A, Spada C. An overview of the mechanisms of HIV-related thrombocytopenia. *Acta Haematol* (2010) **124**:13–8. doi:10.1159/000313782
- Carballal G, Cossio PM, Laguens RP, Ponzinibbio C, Oubina JR, Meckert PC, et al. Junin virus infection of guinea pigs: immunohistochemical and ultrastructural studies of hemopoietic tissue. *J Infect Dis* (1981) **143**:7–14. doi:10.1093/infdis/143.1.7

30. Gibellini D, Clo A, Morini S, Miserocchi A, Ponti C, Re MC. Effects of human immunodeficiency virus on the erythrocyte and megakaryocyte lineages. *World J Virol* (2013) 2:91–101. doi:10.5501/wjv.v2.i2.91
31. Speth C, Löffler J, Krappmann S, Lass-Flörl C, Rambach G. Platelets as immune cells in infectious diseases. *Future Microbiol* (2013) 8:1431–51. doi:10.2217/fmb.13.104
32. Assinger A, Kral JB, Yaiw KC, Schrottmaier WC, Kurzejamska E, Wang Y, et al. Human cytomegalovirus-platelet interaction triggers toll-like receptor 2-dependent proinflammatory and proangiogenic responses. *Arterioscler Thromb Vasc Biol* (2014) 34:801–9. doi:10.1161/ATVBAHA.114.303287
33. Koupnova M, Vitseva O, MacKay CR, Beaulieu LM, Benjamin EJ, Mick E, et al. Platelet-TLR7 mediates host survival and platelet count during viral infection in the absence of platelet-dependent thrombosis. *Blood* (2014) 124:791–802. doi:10.1182/blood-2013-11-536003
34. Coulson BS, Londrigan SL, Lee DJ. Rotavirus contains integrin ligand sequences and a disintegrin-like domain that are implicated in virus entry into cells. *Proc Natl Acad Sci U S A* (1997) 94:5389–94. doi:10.1073/pnas.94.10.5389
35. Mackow ER, Gavrillovskaya IN. Cellular receptors and hantavirus pathogenesis. *Curr Top Microbiol Immunol* (2001) 256:91–115. doi:10.1007/978-3-642-56753-7_6
36. Gupalo E, Kuk C, Qadura M, Buriachkovskaia L, Othman M. Platelet-adenovirus vs. inert particles interaction: effect on aggregation and the role of platelet membrane receptors. *Platelets* (2013) 24:383–91. doi:10.3109/09537104.2012.703792
37. Gavrillovskaya IN, Gorbunova EE, Mackow ER. Pathogenic hantaviruses direct the adherence of quiescent platelets to infected endothelial cells. *J Virol* (2010) 84:4832–9. doi:10.1128/JVI.02405-09
38. Goeijenbier M, van Wissen M, van de Weg C, Jong E, Gerdes VE, Meijers JC, et al. Review: viral infections and mechanisms of thrombosis and bleeding. *J Med Virol* (2012) 84:1680–96. doi:10.1002/jmv.23354
39. Collier BS, Shattil SJ. The GPIIb/IIIa (integrin alphaIIb beta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. *Blood* (2008) 112:3011–25. doi:10.1182/blood-2008-06-077891
40. Moser M, Nieswandt B, Ussar S, Pozgajova M, Fassler R. Kindlin-3 is essential for integrin activation and platelet aggregation. *Nat Med* (2008) 14:325–30. doi:10.1038/nm1722
41. Kahner BN, Kato H, Banno A, Ginsberg MH, Shattil SJ, Ye F. Kindlins, integrin activation and the regulation of talin recruitment to alphaIIb beta3. *PLoS One* (2012) 7:e34056. doi:10.1371/journal.pone.0034056
42. Gong H, Shen B, Flevaris P, Chow C, Lam SC, Voyno-Yasenetskaya TA, et al. G protein subunit Galphai3 binds to integrin alphaIIb beta3 and mediates integrin “outside-in” signaling. *Science* (2010) 327:340–3. doi:10.1126/science.1174779
43. Nunez D, Charriaud-Marlangue C, Barel M, Benveniste J, Frade R. Activation of human platelets through gp140, the C3d/EBV receptor (CR2). *Eur J Immunol* (1987) 17:515–20. doi:10.1002/eji.1830170413
44. Chaipan C, Soilleux EJ, Simpson P, Hofmann H, Gramberg T, Marzi A, et al. DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets. *J Virol* (2006) 80:8951–60. doi:10.1128/JVI.00136-06
45. Othman M, Labelle A, Mazzetti I, Elbatarny HS, Lillicrap D. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. *Blood* (2007) 109:2832–9. doi:10.1182/blood-2006-06-032524
46. Zahn A, Jennings N, Ouwehand WH, Allain JP. Hepatitis C virus interacts with human platelet glycoprotein VI. *J Gen Virol* (2006) 87:2243–51. doi:10.1099/vir.0.18126-0
47. Maugeri N, Cattaneo M, Rovere-Querini P, Manfredi AA. Platelet clearance by circulating leukocytes: a rare event or a determinant of the “immune continuum”? *Platelets* (2014) 25:224–5. doi:10.3109/09537104.2012.763116
48. Grozovsky R, Hoffmeister KM, Falet H. Novel clearance mechanisms of platelets. *Curr Opin Hematol* (2010) 17:585–9. doi:10.1097/MOH.0b013e32833e7561
49. Yeaman MR. Platelets in defense against bacterial pathogens. *Cell Mol Life Sci* (2010) 67:525–44. doi:10.1007/s00018-009-0210-4
50. Bouwman JJ, Visseren FL, Bosch MC, Bouter KP, Diepersloot RJ. Procoagulant and inflammatory response of virus-infected monocytes. *Eur J Clin Invest* (2002) 32:759–66. doi:10.1046/j.1365-2362.2002.01041.x
51. Zapata JC, Cox D, Salvato MS. The role of platelets in the pathogenesis of viral hemorrhagic fevers. *PLoS Negl Trop Dis* (2014) 8:e2858. doi:10.1371/journal.pntd.0002858
52. Alonzo MT, Lacuesta TL, Dimaano EM, Kurosu T, Suarez LA, Mapua CA, et al. Platelet apoptosis and apoptotic platelet clearance by macrophages in secondary dengue virus infections. *J Infect Dis* (2012) 205:1321–9. doi:10.1093/infdis/jis180
53. Antoniak S, Mackman N. Multiple roles of the coagulation protease cascade during virus infection. *Blood* (2014) 123:2605–13. doi:10.1182/blood-2013-09-526277
54. Anderson CL, Chacko GW, Osborne JM, Brandt JT. The Fc receptor for immunoglobulin G (Fc gamma RI) on human platelets. *Semin Thromb Hemost* (1995) 21:1–9. doi:10.1055/s-2007-1000374
55. Cox D, Kerrigan SW, Watson SP. Platelets and the innate immune system: mechanisms of bacterial-induced platelet activation. *J Thromb Haemost* (2011) 9:1097–107. doi:10.1111/j.1538-7836.2011.04264.x
56. Arman M, Krauel K, Tilley DO, Weber C, Cox D, Greinacher A, et al. Amplification of bacteria-induced platelet activation is triggered by Fc gamma RIIIA, integrin alphaIIb beta3, and platelet factor 4. *Blood* (2014) 123:3166–74. doi:10.1182/blood-2013-11-540526
57. Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of “hypersplenic” thrombocytopenia. *J Clin Invest* (1966) 45:645–57. doi:10.1172/JCI105380
58. Zhang W, Nardi MA, Borkowsky W, Li Z, Karpatkin S. Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. *Blood* (2009) 113:4086–93. doi:10.1182/blood-2008-09-181073
59. Weksler BB. Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. *Aliment Pharmacol Ther* (2007) 26(Suppl 1):13–9. doi:10.1111/j.1365-2036.2007.03512.x
60. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. *N Engl J Med* (2007) 357:2227–36. doi:10.1056/NEJMoa073255
61. Louache F, Bettaieb A, Henri A, Oksenhendler E, Farcet JP, Bierling P, et al. Infection of megakaryocytes by human immunodeficiency virus in seropositive patients with immune thrombocytopenic purpura. *Blood* (1991) 78:1697–705.
62. Hottz ED, Oliveira MF, Nunes PC, Nogueira RM, Valls-de-Souza R, Da Poian AT, et al. Dengue induces platelet activation, mitochondrial dysfunction and cell death through mechanisms that involve DC-SIGN and caspases. *J Thromb Haemost* (2013) 11:951–62. doi:10.1111/jth.12178
63. Hottz ED, Medeiros-de-Moraes IM, Vieira-de-Abreu A, de Assis EF, Vals-de-Souza R, Castro-Faria-Neto HC, et al. Platelet activation and apoptosis modulate monocyte inflammatory responses in dengue. *J Immunol* (2014) 193:1864–72. doi:10.4049/jimmunol.1400091
64. Sun DS, King CC, Huang HS, Shih YL, Lee CC, Tsai WJ, et al. Antiplatelet autoantibodies elicited by dengue virus non-structural protein 1 cause thrombocytopenia and mortality in mice. *J Thromb Haemost* (2007) 5:2291–9. doi:10.1111/j.1538-7836.2007.02754.x
65. Hottz ED, Lopes JF, Freitas C, Valls-de-Souza R, Oliveira MF, Bozza MT, et al. Platelets mediate increased endothelium permeability in dengue through NLRP3-inflammasome activation. *Blood* (2013) 122:3405–14. doi:10.1182/blood-2013-05-504449
66. Chuansumrit A, Chaiyaratana W. Hemostatic derangement in dengue hemorrhagic fever. *Thromb Res* (2014) 133:10–6. doi:10.1016/j.thromres.2013.09.028
67. Nascimento EJ, Hottz ED, Garcia-Bates TM, Bozza F, Marques ET Jr, Barratt-Boyes SM. Emerging concepts in dengue pathogenesis: interplay between plasmablasts, platelets, and complement in triggering vasculopathy. *Crit Rev Immunol* (2014) 34:227–40. doi:10.1615/CritRevImmunol.2014010212
68. Iannaccone M, Sitia G, Isogawa M, Whitmire JK, Marchese P, Chisari FV, et al. Platelets prevent IFN-alpha/beta-induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. *Proc Natl Acad Sci U S A* (2008) 105:629–34. doi:10.1073/pnas.0711200105
69. Pozner RG, Ure AE, Jaquenod de Giusti C, D’Atri LP, Italiano JE, Torres O, et al. Junin virus infection of human hematopoietic progenitors impairs in vitro proplatelet formation and platelet release via a bystander effect involving type I IFN signaling. *PLoS Pathog* (2010) 6:e1000847. doi:10.1371/journal.ppat.1000847

70. Wang Q, Miyakawa Y, Fox N, Kaushansky K. Interferon- α directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. *Blood* (2000) **96**:2093–9.
71. Sorensen AL, Rumjantseva V, Nayeib-Hashemi S, Clausen H, Hartwig JH, Wandall HH, et al. Role of sialic acid for platelet life span: exposure of beta-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes. *Blood* (2009) **114**:1645–54. doi:10.1182/blood-2009-01-199414
72. Terada H, Baldini M, Ebbe S, Madoff MA. Interaction of influenza virus with blood platelets. *Blood* (1966) **28**:213–28.
73. Stenberg PE, Levin J, Baker G, Mok Y, Corash L. Neuraminidase-induced thrombocytopenia in mice: effects on thrombopoiesis. *J Cell Physiol* (1991) **147**:7–16. doi:10.1002/jcp.1041470103
74. Turpie AG, Chernesky MA, Larke RP, Packham MA, Mustard JF. Effect of Newcastle disease virus on human or rabbit platelets. Aggregation and loss of constituents. *Lab Invest* (1973) **28**:575–83.
75. Srivastava A, Bruno E, Briddell R, Cooper R, Srivastava C, van Besien K, et al. Parvovirus B19-induced perturbation of human megakaryocytopoiesis in vitro. *Blood* (1990) **76**:1997–2004.
76. Metcalf Pate KA, Lyons CE, Dorsey JL, Shirk EN, Queen SE, Adams RJ, et al. Platelet activation and platelet-monocyte aggregate formation contribute to decreased platelet count during acute simian immunodeficiency virus infection in pig-tailed macaques. *J Infect Dis* (2013) **208**:874–83. doi:10.1093/infdis/jit278
77. Singh MV, Davidson DC, Kiebal M, Maggirwar SB. Detection of circulating platelet-monocyte complexes in persons infected with human immunodeficiency virus type-1. *J Virol Methods* (2012) **181**:170–6. doi:10.1016/j.jviromet.2012.02.005
78. La Russa VF, Innis BL. Mechanisms of dengue virus-induced bone marrow suppression. *Baillieres Clin Haematol* (1995) **8**:249–70. doi:10.1016/S0950-3536(05)80240-9
79. Yeaman MR. Platelets: at the nexus of antimicrobial defence. *Nat Rev Microbiol* (2014) **12**:426–37. doi:10.1038/nrmicro3269
80. Yeaman MR. The role of platelets in antimicrobial host defense. *Clin Infect Dis* (1997) **25**:951–68. doi:10.1086/516120
81. Auerbach DJ, Lin Y, Miao H, Cimbri R, Difiore MJ, Gianolini ME, et al. Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor. *Proc Natl Acad Sci U S A* (2012) **109**:9569–74. doi:10.1073/pnas.1207314109
82. Solomon Tsegaye T, Gniur K, Rahe-Meyer N, Kiene M, Kramer-Kuhl A, Behrens G, et al. Platelet activation suppresses HIV-1 infection of T cells. *Retrovirology* (2013) **10**:48. doi:10.1186/1742-4690-10-48
83. Klinger MH, Wilhelm D, Bubel S, Sticherling M, Schroder JM, Kuhn W. Immunocytochemical localization of the chemokines RANTES and MIP-1 α within human platelets and their release during storage. *Int Arch Allergy Immunol* (1995) **107**:541–6. doi:10.1159/000237097
84. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 α , and MIP-1 β as the major HIV-suppressive factors produced by CD8+ T cells. *Science* (1995) **270**:1811–5. doi:10.1126/science.270.5243.1811
85. Cognasse F, Hamzeh-Cognasse H, Berthet J, Damien P, Lucht F, Pozzetto B, et al. Altered release of regulated upon activation, normal T-cell expressed and secreted protein from human, normal platelets: contribution of distinct HIV-1 gp41 peptides. *AIDS* (2009) **23**:2057–9. doi:10.1097/QAD.0b013e3283330da65
86. Melchjorsen J, Sorensen LN, Paludan SR. Expression and function of chemokines during viral infections: from molecular mechanisms to in vivo function. *J Leukoc Biol* (2003) **74**:331–43. doi:10.1189/jlb.1102577
87. Culley FJ, Pennycook AM, Tregoning JS, Dodd JS, Walzl G, Wells TN, et al. Role of CCL5 (RANTES) in viral lung disease. *J Virol* (2006) **80**:8151–7. doi:10.1128/JVI.00496-06
88. Wareing MD, Lyon AB, Lu B, Gerard C, Sarawar SR. Chemokine expression during the development and resolution of a pulmonary leukocyte response to influenza A virus infection in mice. *J Leukoc Biol* (2004) **76**:886–95. doi:10.1189/jlb.1203644
89. Tyner JW, Uchida O, Kajiwarana N, Kim EY, Patel AC, O'Sullivan MP, et al. CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. *Nat Med* (2005) **11**:1180–7. doi:10.1038/nm1303
90. Katsounas A, Schlaak JF, Lempicki RA. CCL5: a double-edged sword in host defense against the hepatitis C virus. *Int Rev Immunol* (2011) **30**:366–78. doi:10.3109/08830185.2011.593105
91. Wilson SS, Wiens ME, Smith JG. Antiviral mechanisms of human defensins. *J Mol Biol* (2013) **425**:4965–80. doi:10.1016/j.jmb.2013.09.038
92. Mohan KV, Rao SS, Atreya CD. Antiviral activity of selected antimicrobial peptides against vaccinia virus. *Antiviral Res* (2010) **86**:306–11. doi:10.1016/j.antiviral.2010.03.012
93. Lesurtel M, Graf R, Aleil B, Walther DJ, Tian Y, Jochum W, et al. Platelet-derived serotonin mediates liver regeneration. *Science* (2006) **312**:104–7. doi:10.1126/science.1123842
94. Starlinger P, Assinger A, Haegele S, Wanek D, Zikeli S, Schauer D, et al. Evidence for serotonin as a relevant inducer of liver regeneration after liver resection in humans. *Hepatology* (2014) **60**:257–66. doi:10.1002/hep.26950
95. Leon-Ponte M, Ahern GP, O'Connell PJ. Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. *Blood* (2007) **109**:3139–46. doi:10.1182/blood-2006-10-052787
96. Polgar J, Matuskova J, Wagner DD. The P-selectin, tissue factor, coagulation triad. *J Thromb Haemost* (2005) **3**:1590–6. doi:10.1111/j.1538-7836.2005.01373.x
97. Langer HF, Daub K, Braun G, Schonberger T, May AE, Schaller M, et al. Platelets recruit human dendritic cells via Mac-1/JAM-C interaction and modulate dendritic cell function in vitro. *Arterioscler Thromb Vasc Biol* (2007) **27**:1463–70. doi:10.1161/ATVBAHA.107.141515
98. Hagihara M, Higuchi A, Tamura N, Ueda Y, Hirabayashi K, Ikeda Y, et al. Platelets, after exposure to a high shear stress, induce IL-10-producing, mature dendritic cells in vitro. *J Immunol* (2004) **172**:5297–303. doi:10.4049/jimmunol.172.9.5297
99. Elzey BD, Sprague DL, Ratliff TL. The emerging role of platelets in adaptive immunity. *Cell Immunol* (2005) **238**:1–9. doi:10.1016/j.cellimm.2005.12.005
100. Li N. Platelet-lymphocyte cross-talk. *J Leukoc Biol* (2008) **83**:1069–78. doi:10.1189/jlb.0907615
101. Gerdes N, Zhu L, Ersoy M, Hermansson A, Hjendahl P, Hu H, et al. Platelets regulate CD4(+) T-cell differentiation via multiple chemokines in humans. *Thromb Haemost* (2011) **106**:353–62. doi:10.1160/TH11-01-0020
102. Liu CY, Battaglia M, Lee SH, Sun QH, Aster RH, Visentin GP. Platelet factor 4 differentially modulates CD4+CD25+ (regulatory) versus CD4+CD25- (non-regulatory) T cells. *J Immunol* (2005) **174**:2680–6. doi:10.4049/jimmunol.174.5.2680
103. Shi G, Field DJ, Ko KA, Ture S, Srivastava K, Levy S, et al. Platelet factor 4 limits Th17 differentiation and cardiac allograft rejection. *J Clin Invest* (2014) **124**:543–52. doi:10.1172/JCI71858
104. Elzey BD, Grant JF, Sinn HW, Nieswandt B, Walschmidt TJ, Ratliff TL. Cooperation between platelet-derived CD154 and CD4+ T cells for enhanced germinal center formation. *J Leukoc Biol* (2005) **78**:80–4. doi:10.1189/jlb.1104669
105. Elzey BD, Tian J, Jensen RJ, Swanson AK, Lees JR, Lentz SR, et al. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. *Immunity* (2003) **19**:9–19. doi:10.1016/S1074-7613(03)00177-8
106. Danese S, de la Motte C, Reyes BM, Sans M, Levine AD, Fiocchi C. Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. *J Immunol* (2004) **172**:2011–5. doi:10.4049/jimmunol.172.4.2011
107. Iannaccone M, Sitia G, Isogawa M, Marchese P, Castro MG, Lowenstein PR, et al. Platelets mediate cytotoxic T lymphocyte-induced liver damage. *Nat Med* (2005) **11**:1167–9. doi:10.1038/nm1317
108. Iannaccone M, Sitia G, Ruggeri ZM, Guidotti LG. HBV pathogenesis in animal models: recent advances on the role of platelets. *J Hepatol* (2007) **46**:719–26. doi:10.1016/j.jhep.2007.01.007
109. Loria GD, Romagnoli PA, Moseley NB, Rucavado A, Altman JD. Platelets support a protective immune response to LCMV by preventing splenic necrosis. *Blood* (2013) **121**:940–50. doi:10.1182/blood-2011-08-376822
110. Schwartzkopff F, Grimm TA, Lankford CS, Fields K, Wang J, Brandt E, et al. Platelet factor 4 (CXCL4) facilitates human macrophage infection with HIV-1 and potentiates virus replication. *Innate Immun* (2009) **15**:368–79. doi:10.1177/17532425090106171
111. Zaldivar MM, Pauels K, von Hundelshausen P, Berres ML, Schmitz P, Bornemann J, et al. CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator

- of experimental liver fibrosis. *Hepatology* (2010) **51**:1345–53. doi:10.1002/hep.23435
112. Lang PA, Contaldo C, Georgiev P, El-Badry AM, Recher M, Kurrer M, et al. Lang, aggravation of viral hepatitis by platelet-derived serotonin. *Nat Med* (2008) **14**:756–61. doi:10.1038/nm1780
 113. Villinger F, Rollin PE, Brar SS, Chikkala NF, Winter J, Sundstrom JB, et al. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. *J Infect Dis* (1999) **179**(Suppl 1):S188–91. doi:10.1086/514283
 114. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. *Lancet* (2003) **362**:1953–8. doi:10.1016/S0140-6736(03)15012-X
 115. Cummins D, Fisher-Hoch SP, Walshe KJ, Mackie IJ, McCormick JB, Bennett D, et al. A plasma inhibitor of platelet aggregation in patients with Lassa fever. *Br J Haematol* (1989) **72**:543–8. doi:10.1111/j.1365-2141.1989.tb04321.x
 116. Michels M, Alisjahbana B, De Groot PG, Indrati AR, Fijnheer R, Puspita M, et al. Platelet function alterations in dengue are associated with plasma leakage. *Thromb Haemost* (2014) **112**:352–62. doi:10.1160/TH14-01-0056
 117. Rondina MT, Brewster B, Grissom CK, Zimmerman GA, Kastendieck DH, Harris ES, et al. In vivo platelet activation in critically ill patients with primary 2009 influenza A(H1N1). *Chest* (2012) **141**:1490–5. doi:10.1378/chest.11-2860
 118. Bunce PE, High SM, Nadjafi M, Stanley K, Liles WC, Christian MD. Pandemic H1N1 influenza infection and vascular thrombosis. *Clin Infect Dis* (2011) **52**:e14–7. doi:10.1093/cid/ciq125
 119. Starko KM. Salicylates and pandemic influenza mortality, 1918-1919 pharmacology, pathology, and historic evidence. *Clin Infect Dis* (2009) **49**:1405–10. doi:10.1086/606060
 120. Tufano A, Di Capua M, Coppola A, Conca P, Cimino E, Cerbone AM, et al. The infectious burden in atherothrombosis. *Semin Thromb Hemost* (2012) **38**:515–23. doi:10.1055/s-0032-1315759
 121. Rosenfeld ME, Campbell LA. Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. *Thromb Haemost* (2011) **106**:858–67. doi:10.1160/TH11-06-0392
 122. Haji SA, Starling RC, Avery RK, Mawhorter S, Tuzcu EM, Schoenhagen P, et al. Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. *J Heart Lung Transplant* (2004) **23**:277–83. doi:10.1016/S1053-2498(03)00148-7
 123. Simanek AM, Dowd JB, Pawelec G, Melzer D, Dutta A, Aiello AE. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. *PLoS One* (2011) **6**:e16103. doi:10.1371/journal.pone.0016103
 124. Vliegen I, Stassen F, Grauls G, Blok R, Bruggeman C. MCMV infection increases early T-lymphocyte influx in atherosclerotic lesions in apoE knockout mice. *J Clin Virol* (2002) **25**(Suppl 2):S159–71. doi:10.1016/S1386-6532(02)00095-1
 125. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. *Lancet Infect Dis* (2009) **9**:601–10. doi:10.1016/S1473-3099(09)70233-6
 126. Naghavi M, Wyde P, Litovsky S, Madjid M, Akhtar A, Naguib S, et al. Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-deficient mice. *Circulation* (2003) **107**:762–8. doi:10.1161/01.CIR.0000048190.68071.2B
 127. Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. *Circulation* (2001) **103**:2283–8. doi:10.1161/01.CIR.103.18.2283
 128. Damien P, Cognasse F, Lucht F, Suy F, Pozzetto B, Garraud O, et al. Highly active antiretroviral therapy alters inflammation linked to platelet cytokines in HIV-1-infected patients. *J Infect Dis* (2013) **208**:868–70. doi:10.1093/infdis/jit260

Conflict of Interest Statement: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 27 October 2014; paper pending published: 24 November 2014; accepted: 05 December 2014; published online: 18 December 2014.

Citation: Assinger A (2014) Platelets and infection – an emerging role of platelets in viral infection. *Front. Immunol.* 5:649. doi: 10.3389/fimmu.2014.00649

This article was submitted to *Inflammation*, a section of the journal *Frontiers in Immunology*.

Copyright © 2014 Assinger. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.